Target type: biologicalprocess
The chemical reactions and pathways resulting in the formation of an antibacterial peptide with activity against Gram-positive bacteria. [GOC:add]
The biosynthesis of antibacterial peptides active against Gram-positive bacteria is a complex process that involves a series of steps, including gene transcription, translation, protein folding, and post-translational modifications. The genes encoding these peptides are typically located in clusters on the bacterial chromosome, and their expression is often regulated by environmental factors, such as the presence of antibiotics or other stressors.
Once the genes are transcribed, the mRNA transcripts are translated into polypeptide chains. These chains then undergo a series of folding events, which are guided by the peptide sequence and the cellular environment. The folded peptides are often further modified by post-translational processes, such as glycosylation, phosphorylation, or lipidation. These modifications can enhance the peptides' antimicrobial activity, stability, and/or ability to target specific cellular components.
The mechanism of action of antibacterial peptides against Gram-positive bacteria is typically characterized by their ability to disrupt bacterial membranes. Many of these peptides are positively charged and amphipathic, meaning they have both hydrophilic (water-loving) and hydrophobic (water-fearing) regions. This amphipathic nature allows them to interact with the negatively charged bacterial membranes, forming pores that disrupt membrane integrity and lead to cell lysis.
The process of biosynthetic process of antibacterial peptides active against Gram-positive bacteria is an important defense mechanism for these organisms, allowing them to survive in environments with high levels of competing bacteria. However, these peptides can also be exploited as therapeutic agents for the treatment of bacterial infections. Many researchers are currently investigating the potential of these peptides as novel antibiotics, as they offer a number of advantages over traditional antibiotics, including a lower likelihood of resistance development.'
"
Protein | Definition | Taxonomy |
---|---|---|
Nucleotide-binding oligomerization domain-containing protein 2 | A nucleotide-binding oligomerization domain-containing protein 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HC29] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
docetaxel anhydrous | docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. | secondary alpha-hydroxy ketone; tetracyclic diterpenoid | antimalarial; antineoplastic agent; photosensitizing agent |
muramyl dipeptide | glycopeptide | immunological adjuvant | |
3-methyl-7-pentyl-8-(2-phenylethylthio)purine-2,6-dione | oxopurine | ||
3-methyl-7-(phenylmethyl)-8-(propan-2-ylthio)purine-2,6-dione | oxopurine | ||
1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
1-(benzenesulfonyl)-2-benzimidazolamine | sulfonamide | ||
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
pd 166285 | |||
1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
5,6-dimethyl-1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide |